id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-E-0660-0008,FDA,FDA-2010-E-0660,"Letter from U.S. Patent and Trademark Office to Finnegan, Henderson, Farabow Garrett and Dunner LLP",Other,Letter(s),2014-07-02T04:00:00Z,2014,7,2014-07-02T04:00:00Z,,2014-07-02T16:39:32Z,,0,0,09000064817882d9
FDA-2010-E-0660-0007,FDA,FDA-2010-E-0660,FDA\CDER to U.S. Patent and Trademark Office - Lettero,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-27T15:02:27Z,,0,0,090000648119c5ae
FDA-2010-E-0660-0006,FDA,FDA-2010-E-0660,Regulatory Review Period for Purposes of Patent Extension: PROLIA,Notice,General Notice,2012-05-07T04:00:00Z,2012,5,2012-05-07T04:00:00Z,2012-07-07T03:59:59Z,2012-05-07T14:50:41Z,2012-10959,0,0,0900006481006967
FDA-2010-E-0660-0005,FDA,FDA-2010-E-0660,FDA\CDER to U.S. Patent and Trademark Office - Letter,Other,Letter(s),2012-04-18T04:00:00Z,2012,4,2012-04-18T04:00:00Z,,2012-04-18T15:16:11Z,,0,0,0900006480ff39a8
FDA-2010-E-0660-0004,FDA,FDA-2010-E-0660,U.S. Patent & Trademark Office to FDA/CDER - Letter,Other,Letter(s),2012-01-10T05:00:00Z,2012,1,2012-01-10T05:00:00Z,,2012-01-10T16:36:04Z,,0,0,0900006480f91f6c
FDA-2010-E-0660-0003,FDA,FDA-2010-E-0660,FDA/CDER to U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2011-05-03T04:00:00Z,2011,5,2011-05-03T04:00:00Z,,2011-05-03T18:27:40Z,,0,0,0900006480c3e714
FDA-2010-E-0660-0001,FDA,FDA-2010-E-0660,Amgen Inc. - Patent Term Extension Application,Other,APP-Application,2011-05-03T04:00:00Z,2011,5,2011-05-03T04:00:00Z,,2013-07-27T23:41:23Z,,0,0,0900006480bc2a0d
FDA-2010-E-0660-0002,FDA,FDA-2010-E-0660,U.S. Patent and Trademark Office to FDA - Letter,Other,LET-Letter,2011-05-03T04:00:00Z,2011,5,2011-05-03T04:00:00Z,,2013-07-27T23:41:23Z,,0,0,0900006480bc2a0f